Teradx
TeraDx focuses on early cancer detection through microbiome biomarkers and is compatible with standard hospital PCR systems.
Classification
Profile
Funding
Funding details not yet available.
Early cancer detection via microbiome biomarkers using assays fully compatible with standard hospital PCR systems.
Hospitals and clinical laboratories requiring early cancer detection capabilities.
Not specified in the provided snippets.
Online platforms facilitate access to their diagnostic and discovery services.
Bioithas, Chair of Human Microbiota at the San Antonio Catholic University of Murcia, and MiBioPath Microbiota Research Group at FISABIO.
Primarily driven by research and development costs associated with clinical validation of microbiome biomarkers and diagnostic assay development.
Expertise in infectious diseases and microbiome science with over 10 years of translational research experience.
Developing microbiome biomarker assays for early cancer detection compatible with existing PCR infrastructure.
Digital engagement through online channels for diagnostics and research support.
Differentiated by compatibility with standard hospital PCR systems rather than requiring specialized new hardware.
Need for early cancer detection methods that integrate seamlessly with standard hospital PCR systems.
Add a patient-facing digital layer (mobile app) to broaden the market and collect real-world data · Diversify IP to cover analytics algorithms and future biomarker panels · Secure North-American distribution and reimbursement early to reduce time-to-revenue
The strategic moat relies on proprietary microbiome research and exclusive academic partnerships to secure early detection diagnostics in a specialized oncology niche.
Proprietary research resources and key academic partnerships directly enable the development of diagnostic tests, which are then distributed via online channels to hospital customers.
The company’s patent portfolio across Europe, Japan, and pending US/China filings provides a defensible moat[1] · Zubi Labs partnership validates the clinical pathway and offers a credible route to market scaling[2]
Team details not yet available.
No investors recorded yet.